-
-
-
-
-
-
-
Biogen shares rise after Q1 beat; full-year profit outlook slashed
-
-
-
-
-
-
-
Barclays launches U.S. biopharma coverage with four preferred picks
-
-
-
-
-
-
-
JPMorgan on Biogen (BIIB) in 2026: 'Watching Pipeline Derisking Through the Year'
-
-
-
-
-
-
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
-
-
-
-
-
-
JPMorgan Reiterates Neutral Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $315 at Piper Sandler
-
1,205,326 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

